Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: Combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging

BJU International

Volumn 107, Issue 9, 2011, Pages 1411-1418

  Delongchamps, Nicolas Barry ^a   Rouanne, Mathieu ^a   Flam, Thierry ^a   Beuvon, Frédéric ^a   Liberatore, Mathieu ^a   Zerbib, Marc ^a   Cornud, François ^a  

^a Paris Descartes University ^*  (France)

Author keywords

detection; diffusion weighted imaging; dynamic contrast enhanced MRI; localization; prostate cancer

Indexed keywords

GADOLINIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

AGED; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; EPIDEMIOLOGIC METHODS; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 79952282589     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09808.x     Document Type: Article

References (31)

1. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP,. Localized prostate cancer. Relationship of tumour volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71: 933-8 (Pubitemid 23049614)
2. Montironi R, Vela-Navarrete R, Lopez-Beltran A, Mazzucchelli R, Bono A,. 2005 update on pathology of prostate biopsies with cancer. Eur Urol 2006; 49: 441-7 (Pubitemid 43259550)
3. Delongchamps NB, de la Roza G, Jones R, Jumbelic M, Haas GP,. Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer. BJU Int 2009; 103: 49-54
4. Haider MA, van der Kwast TH, Tanguay J, et al,. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007; 189: 323-8 (Pubitemid 47195916)
5. Engelbrecht MR, Huisman HJ, Laheij RJ, et al,. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-54 (Pubitemid 37152132)
6. Langer DL, van der Kwast TH, Evans AJ, Trachtenberg J, Wilson BC, Haider MA,. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009; 30: 327-34
7. Akin O, Sala E, Moskowitz CS, et al,. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-92 (Pubitemid 43830614)
8. Weinmann H-J, Laniado M, Mutzel W,. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16: 167-72
9. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL,. The 2005 International Society of Urological Pathology (ISUP) Concensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29: 1228-42 (Pubitemid 41232997)
10. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaitre L,. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumour volume: correlation with radical prostatectomy findings. J Urol 2006; 176: 2432-7 (Pubitemid 44665992)
11. Carter HB, Brem RF, Tempany CM, et al,. Non palpable prostate cancer: detection with MR imaging. Radiology 1991; 178: 523-5
12. Graser A, Heuck A, Sommer B, et al,. Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology. AJR Am J Roentgenol 2007; 188: 84-90 (Pubitemid 46012493)
13. Nogueira L, Wang L, Fine SW, et al,. Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 2010; 75: 472-7
14. Ikonen S, Karkkainen P, Kivisaari L, et al,. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 1998; 159: 915-9 (Pubitemid 28106556)
15. Noguchi M, Stamey TA, Neal JE, Yemoto CE,. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000; 163: 1751-5 (Pubitemid 30366728)
16. Ellis JH, Tempany C, Sarin MS, Gatsonis C, Rifkin MD, McNeil BJ,. MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis. AJR Am J Roentgenol 1994; 162: 865-72 (Pubitemid 24115872)
17. Cornud F, Beuvon F, Thevenin F, et al,. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer]. Prog Urol 2009; 19: 401-13
18. Girouin N, Mege-Lechevallier F, Tonina Senes A, et al,. Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? Eur Radiol 2007; 17: 1498-509 (Pubitemid 46767598)
19. Li H, Sugimura K, Kaji Y, et al,. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol 2006; 186: 729-42 (Pubitemid 46100257)
20. Puech P, Potiron E, Lemaitre L, et al,. Dynamic contrast-enhanced- magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. Urology 2009; 74: 1094-9
21. Ocak I, Bernardo M, Metzger G, et al,. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Am J Roentgenol 2007; 189: 849
22. Zelhof B, Lowry M, Rodrigues G, Kraus S, Turnbull L,. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int 2009; 104: 621-7
23. Nakashima J, Tanimoto A, Imai Y, et al,. Endorectal MRI for prediction of tumour site, tumour size, and local extension of prostate cancer. Urology 2004; 64: 101-5 (Pubitemid 38887587)
24. Noworolski SM, Vigneron DB, Chen AP, Kurhanewicz J,. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn Reson Imaging 2008; 26: 1071-80
25. Kozlowski P, Chang SD, Jones EC, Berean KW, Chen H, Goldenberg SL,. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J Magn Reson Imaging 2006; 24: 108-13
26. Tanimoto A, Nakashima J, Kohno H, Shinmoto H, Kuribayashi S,. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007; 25: 146-52 (Pubitemid 46095209)
27. Yoshizako T, Wada A, Hayashi T, et al,. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol 2008; 49: 1207-13
28. Schlemmer HP, Merkle J, Grobholz R, et al,. Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004; 14: 309-17 (Pubitemid 38181089)
29. Josefsson A, Wikstrom P, Granfors T, et al,. Tumour size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumours in patients with long follow-up and non-curative treatment. Eur Urol 2005; 48: 577-83 (Pubitemid 41278582)
30. Langer DL, van der Kwast TH, Evans AJ, et al,. Intermixed normal tissue within prostate cancer: effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008; 249: 900-8
31. Weinreb JC, Blume JD, Coakley FV, et al,. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy. Results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 2009; 251: 122-33